Holen Sie sich die Stockscreener-App
7.56
5.59%
0.42
Schlusskurs vom Vortag:
$7.14
Offen:
$7.25
24-Stunden-Volumen:
245.34K
Relative Volume:
0.13
Marktkapitalisierung:
$846.13M
Einnahmen:
$24.30M
Nettoeinkommen (Verlust:
$-145.57M
KGV:
-5.6842
EPS:
-1.33
Netto-Cashflow:
$-149.17M
1W Leistung:
-0.54%
1M Leistung:
+15.46%
6M Leistung:
+434.70%
1J Leistung:
+9.90%
1-Tages-Spanne:
$7.25
$7.62
1-Wochen-Bereich:
$6.78
$7.725
52-Wochen-Spanne:
$1.03
$8.80
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
7.605 | 794.40M | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.67 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.15 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.31 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.29 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.50 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Best data tools to analyze Tango Therapeutics Inc. stockMarket Activity Summary & Capital Efficiency Focused Strategies - newser.com
Detecting price anomalies in Tango Therapeutics Inc. with AIWeekly Risk Report & Reliable Intraday Trade Alerts - newser.com
Developing predictive dashboards with Tango Therapeutics Inc. dataJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Tango Therapeutics Inc. stock trendline breakdownIPO Watch & Reliable Entry Point Alerts - newser.com
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $10.50 Average PT from Analysts - Defense World
Will Tango Therapeutics Inc. benefit from macro trendsChart Signals & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Tango Therapeutics Inc. holders2025 Market Overview & Fast Moving Trade Plans - newser.com
Market reaction to Tango Therapeutics Inc.’s recent newsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Real time alert setup for Tango Therapeutics Inc. performance2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Tango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Historical volatility pattern of Tango Therapeutics Inc. visualizedMarket Activity Summary & Fast Moving Market Watchlists - newser.com
Real time social sentiment graph for Tango Therapeutics Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - newser.com
Tango To Present At The 2025 SITC Annual Meeting — Will New Insights Make Waves? - RTTNews
Regression analysis insights on Tango Therapeutics Inc. performanceTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Is Tango Therapeutics Inc. building a consolidation base2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials - Investing.com UK
Tango Therapeutics to Present First Clinical Data from - GlobeNewswire
First clinical data: TNG260 — Tango Therapeutics presents Phase 1/2 results at SITC Nov 7 - Stock Titan
Building trade automation scripts for Tango Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-05 03:22:51 - newser.com
Piper Sandler Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Multi factor analysis applied to Tango Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - newser.com
How to use Fibonacci retracement on Tango Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone - Markets Mojo
Healthcare veteran David Wilkinson to join Tango as chief financial officer - MarketScreener
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
Published on: 2025-09-30 04:30:06 - newser.com
Published on: 2025-09-30 03:51:20 - newser.com
Major Shareholder Sells Off Tango Therapeutics Stock in Multi-Million Dollar Deal! - TipRanks
Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 Shares - MarketBeat
Tango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc. - Defense World
Tango Therapeutics Hits New 52-Week High at $8.56 - Markets Mojo
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):